Dermatology companies
28 listed dermatology companies, largest first, with lead program and the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| Veradermics, Inc | MANE | VDPHL01 | Pattern hair loss (male and female) | H2 2026 — Topline data from Part B of Study '302' (male pattern hair loss) anticipated in the second half of 2026. |
| Oruka Therapeutics, Inc. | ORKA | ORKA-001 | moderate-to-severe plaque psoriasis (EVERLAST-A Phase 2a, EVERLAST-B Phase 2b) | Q4 2026 — Week 16 data |
| Arcutis Biotherapeutics, Inc. | ARQT | ZORYVE (roflumilast) topical | Plaque psoriasis, seborrheic dermatitis, atopic dermatitis | February 23, 2027 — FDA PDUFA action on sNDA |
| Palvella Therapeutics, Inc. | PVLA | QTORIN 3.9% rapamycin anhydrous gel | Microcystic lymphatic malformations | H2 2026 — Phase 2 trial initiation |
| Absci Corp | ABSI | ABS-201 | Androgenetic alopecia (persistent hair loss) | Q4 2026 — Start Phase 2 in endometriosis |
| Evolus, Inc. | EOLS | Jeuveau (prabotulinumtoxinA-xvfs) | temporary improvement in appearance of moderate to severe glabellar lines (aesthetic) | H2 2026 — FDA PMA approval |
| Turn Therapeutics Inc. | TTRX | GX-03 | Atopic dermatitis / moderate-to-severe eczema (topical PHMB-based immunomodulator) | June 2027 — Initiation of Phase 2a study |
| Clinuvel Pharmaceuticals Ltd | CUVL | SCENESSE (afamelanotide 16mg) | Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP); vitiligo (with NB-UVB) under study in CUV105 | December 2026 — Top line results |
| Vanda Pharmaceuticals Inc. | VNDA | Quimilza (imsidolimab) | Generalized pustular psoriasis (GPP) | December 12, 2026 — FDA PDUFA action date for BLA |
| Sol-Gel Technologies Ltd. | SLGL | SGT-610 (patidegib gel 2%) | chronic use and prevention of new basal cell carcinomas in Gorlin syndrome | — |
| MediWound Ltd. | MDWD | NexoBrid | enzymatic eschar removal in deep partial- and full-thickness thermal burns | H2 2026 — Initiate Phase II study in diabetic foot ulcers |
| Journey Medical Corp | DERM | Emrosi (minocycline modified-release capsules 40 mg) | Inflammatory lesions of rosacea in adults | — |
| Organogenesis Holdings Inc. | ORGO | ReNu | wound healing (type not specified) | April 24, 2027 — PDUFA target action date |
| SkinHealth Systems Inc. | SKIN | Hydrafacial (Syndeo delivery system and consumables) | professional skin health treatments | — |
| Pelthos Therapeutics Inc. | PTHS | Zelsuvmi (berdazimer) topical gel, 10.3% | molluscum contagiosum | Q1 2027 — Commercial relaunch |
| Fortress Biotech, Inc. | FBIO | Emrosi (DFD-29) and Journey Medical marketed dermatology portfolio; ZYCUBO (CUTX-101) | inflammatory lesions of rosacea (Emrosi); Menkes disease (ZYCUBO) | H2 2026 — topline data, Phase 2 in adults co-infected with HIV and CMV |
| Verrica Pharmaceuticals Inc. | VRCA | YCANTH (VP-102, cantharidin) | Molluscum contagiosum | 2027 — Phase 3 top-line data |
| Spectral AI, Inc. | MDAI | DeepView System (DeepView-AI Burn software with SnapShot MSI imaging device) | Burn wound healing assessment | 2026 — First commercial sales in the United States |
| SANUWAVE Health, Inc. | SNWV | UltraMIST system | Acute and chronic wounds (diabetic foot ulcers, venous leg ulcers, other wound types) - wound healing and debridement | — |
| Quoin Pharmaceuticals Ltd. | QNRX | QRX003 | Netherton Syndrome | Q4 2026 — Quoin expects to complete recruitment of all 20 participants in Phase 2/3 Netherton Syndrome study CL-QRX003-004 by the end of 2026. |
| Rocket One Inc. | RKTO | HT-001 | Dermatological side effects (rash) of EGFR inhibitor cancer therapy | — |
| Vyome Holdings, Inc. | HIND | VT-1953 | signs and symptoms (malodor, pain) of malignant fungating wounds in advanced cancer | date not stated — Type C meeting with FDA on pivotal clinical development program in malignant fungating wounds |
| Biofrontera Inc. | BFRI | Ameluz (aminolevulinic acid gel) with RhodoLED lamps, photodynamic therapy | Actinic keratosis (face and scalp); label-expansion programs in superficial basal cell carcinoma, AK trunk/extremities, acne | Q4 2026 — Biofrontera plans to officially launch the sBCC indication late in the fourth quarter of 2026 through the first quarter of 2027. |
| Soligenix, Inc. | SNGX | SGX302 (synthetic hypericin sodium, photodynamic therapy) | mild-to-moderate psoriasis | — |
| FibroBiologics, Inc. | FBLG | CYWC628 | Diabetic foot ulcers (wound healing) | H2 2026 — Six-week interim safety and primary efficacy data once 28 patients per arm complete 6 weeks |
| Sonoma Pharmaceuticals, Inc. | SNOA | Microcyn / stabilized hypochlorous acid (HOCl) product line | Wound care, dermatology, eye care, podiatry, animal health, disinfectants | — |
| Azitra, Inc. | AZTR | ATR-04 | EGFR-inhibitor-associated papulopustular rash in cancer patients | Q4 2026 — Initial data from Cohort 1 of Phase 1/2 trial |
| Nexgel, Inc. | NXGL | Hydrogel contract manufacturing and branded OTC consumer products (MedaGel, Kenkoderm, Silly George) | — | — |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.